The purpose of this study was to evaluate the risk factors, outcomes and epidemiology associated with Clostridium difficile infection (CDI) in patients with haematological malignancies in a tertiary care hospital in China. C. difficile screening was performed on patients admitted for chemotherapy or haematopoietic stem cell transplantation between 2009 and 2013. C. difficile isolates were analysed by multilocus sequence typing, and a retrospective chart review was performed on all patients with a positive toxin assay. CDI was diagnosed in 21 haematologyoncology ward patients and 14 marrow transplantation service patients for a cumulative incidence of 1.89/1000 and 3.69/1000 patient-days, respectively. Univariate analyses showed that patients who received etoposide had an increased risk of CDI (odds ratio 4.25, 95 % confidence interval 1.32-13.64). There was only one patient death, for which CDI was not the primary cause. Ten sequence types (STs) were identified, of which ST-3 and ST-54 were the most common; the hypervirulent ST-1 (ribotype 027) and ST-11 (ribotype 078) C. difficile strains were not detected in the patients in this study. The incidence of CDI did not differ between patients receiving chemotherapy and those receiving haematopoietic stem cell transplantation. The only risk factor for chemotherapy patients was treatment with etoposide.
INTRODUCTION
Clostridium difficile, an anaerobic, Gram-positive, sporeforming bacterium, was first isolated in 1935 and described as a cause of diarrhoea in 1978 in a patient with pseudomembranous colitis. According to the Centers for Disease Control and Prevention, infection with C. difficile has surpassed that with meticillin-resistant Staphylococcus aureus as the most common hospital-onset, healthcarefacility-associated infection, and is the leading cause of healthcare-associated infectious diarrhoea (CDC, 2013) .
Patients receiving chemotherapy for haematological malignancies or undergoing haematopoietic stem cell transplants (HSCTs) are at a high risk for C. difficile infection (CDI). Gorschlüter et al. (2001) reported that CDI occurs in 7.0 % of all courses of myelosuppressive chemotherapy, and Chopra et al. (2010) found that CDI rates in HSCT recipients are nine times higher than in the general patient population. Patients who are treated for haematological malignancies are particularly susceptible to C. difficile because of their long hospitalizations, irritation of the intestinal mucosa by chemotherapy drugs (Bartlett, 1992) and extended exposure to antibiotics, which can cause changes to the microbiota of the gut. Healthy gastrointestinal microbial communities play an essential role in resisting C. difficile colonization, and diarrhoea is common in chemotherapy patients and HSCT recipients. Although chemotherapyassociated CDI is much less common than CDI secondary to antibiotic treatment, the proposed mechanism is similar to antibiotic-induced alteration of the bowel microbiota.
Since the first case of chemotherapy-associated CDI was reported in 1981, chemotherapeutic agents have been considered independent risk factors for the development of CDI. Several studies have shown that antineoplastic agents, such as methotrexate and doxorubicin, have intrinsic antimicrobial activity, alter the bowel flora and precipitate an overgrowth of C. difficile (Anand & Glatt, 1993) .
Antineoplastic drugs can also damage the gut and induce severe inflammatory changes, promote an anaerobic environment, and decrease degradation of C. difficile toxins by promoting an accumulation of albumin and other protein-rich fluids in the lumen of the gut (Anand & Glatt, 1993; Jarvis & Shevchuk, 1997) . Reports show a 76-91 % incidence of diarrhoea in HSCT recipients (Tomblyn et al., 2002) , and the incidence of CDI in these patients can be as high as 20 % (Bobak et al., 2008) .
It is a challenge for the clinician to differentiate CDI in HSCT recipients from other causes of diarrhoea, such as reactions to conditioning regimens and graft-versus-host disease (GVHD) of the gastrointestinal tract. Although the exact relationship between GVHD and CDI remains unknown, they may be interrelated, as studies have shown an increased risk for gut and severe GVHD after CDI (Chakrabarti et al., 2000; Dubberke et al., 2010) .
The epidemiology of CDI in immunocompromised hosts is likely different from other patients due to repeated cycles of chemotherapy and hospitalization. Cohen et al. (1997) isolated diverse C. difficile strains in their oncology wards and observed that the strains were distinct from those in general wards where a predominant environmental isolate was associated in 82 % of CDI cases. Chopra et al. (2007) reported that the wide diversity of the C. difficile strains in their study strongly suggests that the epidemiology of CDI in this population is complex. The purpose of this article was to evaluate the risk factors, outcomes and epidemiology associated with CDI in Chinese chemotherapy patients and HSCT recipients. To that end, we performed a retrospective, single-centre study that assessed the incidence and risk factors associated with CDI in patients with haematological malignancies in a Chinese tertiary care hospital.
METHODS
Patient population and disease definitions. We retrospectively analysed the cases of 200 consecutive patients who developed diarrhoea at our hospital, including 97 patients who were treated with chemotherapy and 103 patients who received HSCTs during the 4-year period between September 1 2009 and August 31 2013. The First Affiliated Hospital of Zhejiang University is a tertiary care academic medical centre in Eastern China with 2500 beds in 30 wards. Patients were identified by reviewing the census records kept on their patient care unit, which contained pertinent information on all admitted patients. Death certificates provided information on dates and causes of death.
The criteria used for inclusion were: (i) patients who were treated with chemotherapy; (ii) patients who received HSCTs; and (iii) patients who developed diarrhoea while hospitalized. Diarrhoea was defined as the discharge of semi-solid or liquid stool twice or more during a 24 h period after admission. If a patient had more than one episode of CDI during the study period, the hospitalization during which the first episode of CDI occurred was used as the index hospitalization. (Guddati et al., 2014) .
Laboratory methods. All stool samples (semi-formed, unformed or liquid) submitted to the hospital clinical microbiology laboratory were tested for C. difficile, whether the clinician requested these tests or not. Stool specimens were diluted with alcohol to a final concentration of 75 % for spore selection before anaerobic isolation for C. difficile was performed using cycloserine-cefoxitin-taurocholate agar (Oxoid) supplemented with 7 % sheep's blood. Cultures were incubated at 35 uC for 48 h. Strains were identified using morphological features (flat, yellow, ground-glass appearance of colonies) and were confirmed by matrix-assisted laser desorption ionization-time of flight MS using the Microflex LT system (Bruker Daltonik).
C. difficile isolates were analysed by PCR to detect toxin A and B genes (tcdA and tcdB, respectively) as described by Kato et al. (2001) . The primer pairs were NK9-NK11 (1200 bp product) for the repetitive domain of tcdA, and NK104-NK105 (200 bp product) for tcdB. The binary toxin genes cdtA and cdtB were detected as described by Stubbs et al. (2000) .
Multilocus sequence typing (MLST) with seven housekeeping genes (adk, atpA, dxr, glyA, recA, soda and tpi) was performed on all isolates as described by Griffiths et al. (2010) . DNA sequences were submitted to the MLST database (http://pubmlst.org/cdifficile/) to obtain the sequence type (ST).
Statistical analysis. The data were processed and univariate analyses were performed using SPSS v. 20 software (IBM). Odds ratios and their 95 % confidence intervals are presented for categorical variables. The Student's t-test was used for comparing differences between mean values, and x 2 analysis was used to compare proportions, except when ¡5 items were analysed in any one proportion, in which case a two-tailed Fisher exact test was employed. P,0.05 was considered as statistically significant.
RESULTS

Findings in patients receiving chemotherapy
The study included 97 consecutive patients receiving chemotherapy for haematological malignancies. Twentyone of these patients were diagnosed with CDI. The mean age of patients with CDI was 42.9 years (range 13-77 years), and 23.8 % (5/21) were ¢60 years. All 21 patients with CDI had received a median of three courses of antibiotics (range 1-9) before the disease manifested, including carbapenems (n512), antifungal agents (n512), fluoroquinolone (n511) and third-generation cephalosporins (n59). There were no significant differences between patients with and without CDI regarding the types or frequency of antibiotics (Table 1) . The chemotherapy drugs employed were cytarabine, cyclophosphamide, vincristine (or vinblastine), corticosteroids, Only seven patients received CDI treatment with oral metronidazole (n51), intravenous metronidazole (n51) or oral vancomycin (n55). Oral berberine, a traditional antimicrobial Chinese plant, was given to 52.4 % (11/21) of the CDI patients, and these patients did not experience a recurrence: berberine alone (n57), berberine with vancomycin (n52) or berberine with metronidazole (n52). One patient with CDI died, but CDI was not considered the primary cause of death. Table 2 provides a general description of laboratory data for patients receiving chemotherapy. CDI patients had a significantly lower platelet count than those without infection (P,0.05).
Findings in HSCT patients
There were 103 patients in the HSCT group, including 14 patients with CDI and 89 patients with non-CDI diarrhoea.
The mean age of patients with CDI was 29.4 years (range 17-46 years). Approximately 79 % (11/14) of these CDI cases occurred during the peritransplant period within 30 days of HSCT. The characteristics of the HSCT recipients with CDI and without CDI are compared in Tables 3 and 4 . There were no significant differences in the demographics of the groups. All patients had received at least one antibiotic within 30 days before the CDI test. Antifungal agents were the most common (85.7 %) of the drugs that HSCT patients received, as well as cyclosporine, methotrexate and mycophenolate mofetil. Only half of the patients with CDI received CDI treatment, including oral metronidazole (n51), oral vancomycin combined with oral metronidazole (n55) and oral vancomycin (n51). No patients died in the CDI group, but 11 patients died in the non-CDI group.
Molecular epidemiology of the isolates
All isolated toxigenic C. difficile strains were analysed by MLST and divided into 13 different STs. The most commonly observed types were ST-54 (17.1 %) and ST-3 (17.1 %), followed by ST-35 (14.3 %) and ST-37. Neither ST-1 (BI/NAP1/027) nor ST-11 (ribotype 078) was seen in our HSCT patients (Fig. 1) . Among the 21 isolates from patients receiving chemotherapy, ten different STs were identified, of which ST-3, ST-35 and ST-54 were the most common, but none were .19 % of the total cases. Among the 14 isolates from the HSCT group, ten different STs were identified, of which ST-3, ST-37, ST-39 and ST-54 were the most common, but combined were ,14.3 % of the total cases.
Summary of findings
Over the 4-year study period, 35 patients were diagnosed with CDI during hospitalization, including 21 patients receiving chemotherapy and 14 receiving HSCTs. The cumulative incidence of CDI in these patients was 1.89/ 1000 and 3.69/1000 patient-days, respectively. According to MLST analysis, none of the isolates were identified as ST-1 (BI/NAP1/027) or ST-11 (ribotype 078).
DISCUSSION
The morbidity and mortality of CDI have increased in recent years, and it has progressed from a nuisance disease with minor morbidity to a major concern for health care systems and clinicians (Verma & Makharia, 2011) . Although CDI occurs in immunocompromised populations, it has not received the same attention as invasive fungal or viral infections in these patients until recently.
During our 4-year study, we observed 35 cases of CDI in patients with haematological malignancies, the incidence of which, though not significant, was lower in patients receiving HSCTs compared to those receiving chemotherapy (13.6 vs 21.6 %). Most episodes of CDI in our HSCT recipients (64.3 %) occurred in the peritransplant period within 30 days of HSCT, which is similar to the 71 % reported by Chopra et al. (2011) . In agreement with their study, conventional risk factors, such as exposure to antibiotics and conditioning regimens, likely play significant roles in the pathogenesis of CDI in this population, and all HSCT recipients who develop diarrhoea during the peritransplant period should be tested for CDI.
Severe alteration of the gut microbiome by antibiotics alters the normal bowel microbiota and causes intestinal inflammation and mucosal necrosis that promote anaerobic bacterial growth. This destroys the organisms that block C. difficile colonization (Chopra et al., 2010) , which is considered the major trigger for CDI. Clindamycin, third-generation cephalosporins and fluoroquinolones are the most commonly used antibiotics in the treatment of haematological malignancies, and are most often associated with CDI (Owens et al., 2008) . All our patients, including those without CDIs, had received antibiotics during the 6 weeks before they developed the disorder, though only fluoroquinolone was associated with CDIs in the HSCT group. In a review by Jarvis & Shevchuk (1997), 17 antineoplastic agents, including cyclophosphamide, cytarabine and etoposide, were all associated with CDIs. Gorschlüter et al. (2001) reported a CDI incidence of 5-7 % per course of chemotherapy regardless of the drug. Although etoposide was the only drug shown to be associated with CDI in this study, combinations of drugs are usually administered to patients with haematological malignancies, so it is impossible to attribute complete causality to any single agent.
Diarrhoea is common in almost 90 % of HSCT recipients for multiple reasons, including GVHD (Bobak et al., 2008) . A bidirectional relationship between CDI and GVHD has been highlighted in a number of recent studies (Murphy & Nguyen, 2011; Alonso & Marr, 2013) . In this study, acute GVHD and grades II-IV GVHD were common in both CDI and non-CDI patients (57.1 and 49.3 %, respectively). More clinical and experimental data are needed to determine whether there is a true cause-and-effect relationship between CDI and GVHD development, or if these results represent sampling bias.
In previous retrospective studies, patients with CDI were found to have higher mean white blood cell and platelet counts, and lower levels of albumin, when compared to patients without CDI (Albrich & Rimland, 2007) .
Thrombocytosis is a well-recognized, non-specific phenomenon in several inflammatory conditions, both infectious and non-infectious. In CDI, C. difficile toxin A and B can promote the release of cytokines such as IL-1, IL-6 and IL-8, which are associated with reactive thrombocytosis (Kaser et al., 2001) , and leukocytosis. Although hypoalbuminaemia and thrombocytosis are considered markers of CDI in the general patient population (Kyne et al., 2000) , CDI patients in the chemotherapy group in our study had significantly lower platelet counts compared to patients without CDI. Thus, recognized markers of CDI may not universally apply to all cases, such as in immunocompromised patients, for whom additional studies are needed to determine the relationship between CDI and platelet count.
Although many European countries have national or regional networks for CDI surveillance (European Commission, 2012), these do not exist in China. Limited clinical awareness of CDI in China is due to methodological limitations in clinical microbiology laboratories and the low number of reported cases (Chen et al., 2014) . Physicians requested CDI screening in less than half of the CDI cases in our study, including in 33.3 % of chemotherapy patients and 42.8 % of patients receiving HSCTs. This is similar to a report from Spain, where almost half of the S.-L. Gu and others CDI cases detected in hospital reference laboratories were not accompanied by a request to check for CDI by the attending clinician (Alcalá et al., 2012) . All CDI patients whose clinicians requested a CDI test were treated with standard regimens of oral metronidazole, vancomycin or a combination of both for 10-14 days, and recovered after treatment. There was only one death among our study subjects, and it occurred after the diarrhoea had stopped and was not considered to be the primary cause of death.
Interestingly, nearly half of all patients with diarrhoea in our study were treated with berberine when their symptoms first appeared, and there were no severe cases of CDI found in this study. Berberine is a traditional Chinese medicine that has been used to treat bacterial or secretory diarrhoea for 12 000 years in China. Jeong et al. (2009) reported that berberine inhibits LPS-induced expression of proinflammatory genes in macrophages. Additional studies are needed to determine whether berberine might be a new useful therapeutic agent to alleviate clinical symptoms of CDI.
MLST analysis identified 13 different STs in the stool samples, among which ST-3 and ST-54 were the most common. These findings support results from our previous work showing that ST-54 is the most prevalent type in our hospital, though ST-3 was not a major type in that study (Chen et al., 2014) . This difference in the epidemiology of endemic CDI between the immunocompromised patients and general hospitalized patients may be due to certain risk factors, such as exposure to antineoplastic chemotherapy or steroids, and the presence of haematological malignancy. Furthermore, the hypervirulent C. difficile ST-1 (ribotype 027) and ST-11 (ribotype 078) strains were not seen in our study. Based on a previous study (Kato et al., 2001) , we suspected that cross-transmission among patients through healthcare workers and environmental contamination during long hospital stays were a source of CDI, but we did not find any clustering of cases that would indicate this.
There are several limitations inherent to this study. First, the population size is small. Although the study period was from September 1 2009 to August 31 2013, only 200 patients were included. Second, as a retrospective study, bias can occur and it is not easy to infer a causal relationship. Third, patients receiving chemotherapy were not divided into subgroups based on chemotherapy regimens.
In conclusion, during our 4-year study, we saw 35 cases of CDI in patients with haematological malignancies. Patients who received the chemotherapy drug etoposide had an increased risk of developing this disorder. It is worth emphasizing that chemotherapy drugs can cause CDI without the concurrent use of antibiotics. We suggest that clinicians immediately run a CDI test on the stool of any chemotherapy patient who develops diarrhoea within the first 30 days after their course of chemotherapy. In our study, we often used berberine to alleviate symptoms, and none of our cases of CDI became severe. Although the mechanism of action of berberine in CDI is not clear, it might alleviate clinical symptoms of CDI.
